keyword
MENU ▼
Read by QxMD icon Read
search

AHF

keyword
https://www.readbyqxmd.com/read/28508293/influenza-infection-and-heart-failure-vaccination-may-change-heart-failure-prognosis
#1
REVIEW
Nikolaos P E Kadoglou, Frank Bracke, Tim Simmers, Sotirios Tsiodras, John Parissis
The interaction of influenza infection with the pathogenesis of acute heart failure (AHF) and the worsening of chronic heart failure (CHF) is rather complex. The deleterious effects of influenza infection on AHF/CHF can be attenuated by specific immunization. Our review aimed to summarize the efficacy, effectiveness, safety, and dosage of anti-influenza vaccination in HF. In this literature review, we searched MEDLINE and EMBASE from January 1st 1966 to December 31st, 2016, for studies examining the association between AHF/CHF, influenza infections, and anti-influenza immunizations...
May 15, 2017: Heart Failure Reviews
https://www.readbyqxmd.com/read/28501384/acute-heart-failure-in-the-emergency-department-the-safe-simeu-epidemiological-study
#2
Andrea Fabbri, Giulio Marchesini, Giorgio Carbone, Roberto Cosentini, Annamaria Ferrari, Mauro Chiesa, Alessio Bertini, Federico Rea
BACKGROUND: Patients with acute heart failure (AHF) have high rates of attendance to emergency departments (EDs), with significant health care costs. OBJECTIVES: We aimed to describe the clinical characteristics of patients attending Italian EDs for AHF and their diagnostic and therapeutic work-up. METHODS: We carried out a retrospective analysis on 2683 cases observed in six Italian EDs for AHF (January 2011 to June 2012). RESULTS: The median age of patients was 84 years (interquartile range 12), with females accounting for 55...
May 10, 2017: Journal of Emergency Medicine
https://www.readbyqxmd.com/read/28501337/late-in-hospital-management-of-patients-hospitalized-with-acute-heart-failure
#3
REVIEW
Nicole B Cyrille, Snehal R Patel
Acute Heart Failure (AHF) hospitalization presents a significant financial burden and portends a poor prognosis following discharge. As such, there has been significant emphasis on the late inpatient management of patients hospitalized with AHF to ensure successful transition to the outpatient setting and to reduce overall readmission and mortality rates. Thorough discharge planning and a multidisciplinary team approach are essential and as outlined in this review should focus on four key elements: the assessment of patients' readiness for discharge, optimization of goal directed medical therapy and appropriate device therapy, patient education and transition to the outpatient care...
May 10, 2017: Progress in Cardiovascular Diseases
https://www.readbyqxmd.com/read/28499668/a-multicenter-feasibility-study-on-ultrafiltration-via-a-single-peripheral-venous-access-in-acute-heart-failure-with-overt-fluid-overload
#4
Marco Morpurgo, Mario Pasqualini, Maria Cristiana Brunazzi, Gabriele Vianello, Roberto Valle, Loris Roncon, Fulvio Fiorini, Nadia Aspromonte, Mario Barbiero, Marco Goldoni, Giancarlo Marenzi
OBJECTIVES: The need for a central venous catheter has limited the widespread use of ultrafiltration in daily clinical practice for the treatment of acute heart failure (AHF) with overt fluid overload. We evaluated the feasibility of a new ultrafiltration device, the CHIARA (Congestive Heart Impairment Advanced Removal Approach) system, that utilizes a single-lumen cannula (17G, multi-hole) inserted in a peripheral vein of the arm. METHODS: In this multicenter, prospective, feasibility study, consecutive ultrafiltration treatments (lasting ≥6 hours and with an ultrafiltration rate ≥100ml/h) with the CHIARA device and a single peripheral venous approach were performed at 6 Italian hospitals...
May 2, 2017: International Journal of Cardiology
https://www.readbyqxmd.com/read/28496020/predictors-of-long-term-mortality-in-patients-with-acute-heart-failure
#5
Mengchao Jin, Siqi Wei, Rongrong Gao, Kai Wang, Xuejuan Xu, Wenming Yao, Haifeng Zhang, Yanli Zhou, Dongjie Xu, Fang Zhou, Xinli Li
To investigate parameters which were related with long-term mortality in patients hospitalized for acute heart failure (AHF).A total of 287 patients with AHF presenting to the First Affiliated Hospital of Nanjing Medical University were enrolled into the registry from April 2012 to January 2015. The primary endpoint was all-cause mortality within 1 year; the association between variables and prognosis was assessed after 1 year.Among the 287 patients, 17 did not continue follow-up and 47 (17.4%) passed away...
May 12, 2017: International Heart Journal
https://www.readbyqxmd.com/read/28485200/assessment-of-early-treatment-response-by-rapid-cardiothoracic-ultrasound-in-acute-heart-failure-cardiac-filling-pressures-pulmonary-congestion-and-mortality
#6
Jonas Öhman, Veli-Pekka Harjola, Pasi Karjalainen, Johan Lassus
BACKGROUND: It is unclear how to optimally monitor acute heart failure (AHF) patients. We evaluated the timely interplay of cardiac filling pressures, brain natriuretic peptides (BNPs), lung ultrasound (LUS) and symptoms during AHF treatment. METHODS: We enrolled 60 patients who had been hospitalised for AHF. Patients were examined with a rapid cardiothoracic ultrasound (CaTUS) protocol, combining LUS and focused echocardiographic evaluation of cardiac filling pressures (i...
May 1, 2017: European Heart Journal. Acute Cardiovascular Care
https://www.readbyqxmd.com/read/28484958/markers-of-diuretic-resistance-in-emergency-department-patients-with-acute-heart-failure
#7
Andrew Doering, Cathy A Jenkins, Alan B Storrow, JoAnn Lindenfeld, Gregory J Fermann, Karen F Miller, Matthew Sperling, Sean P Collins
BACKGROUND: Loop diuretics are common therapy for emergency department (ED) patients with acute heart failure (AHF). Diuretic resistance (DR) is a term used to describe blunted natriuretic response to loop diuretics. It would be important to detect DR prior to it becoming clinically apparent, so early interventions can be initiated. However, several definitions have been proposed, and it is not clear if they identify similar patients. We compared these definitions and described the clinical characteristics of patients who fulfilled them...
December 2017: International Journal of Emergency Medicine
https://www.readbyqxmd.com/read/28479167/trajectory-of-congestion-metrics-by-ejection-fraction-in%C3%A2-patients-with-acute-heart-failure-from-the-heart-failure%C3%A2-network
#8
Andrew P Ambrosy, Ankeet S Bhatt, Dianne Gallup, Kevin J Anstrom, Javed Butler, Adam D DeVore, G Michael Felker, Marat Fudim, Stephen J Greene, Adrian F Hernandez, Jacob P Kelly, Marc D Samsky, Robert J Mentz
Differences in the clinical course of congestion by underlying ejection fraction (EF) have not been well-characterized in acute heart failure (AHF). A post hoc analysis was performed using pooled data from the Diuretic Optimization Strategies Evaluation in Acute Heart Failure, Cardiorenal Rescue Study in Acute Decompensated Heart Failure, and Renal Optimization Strategies Evaluation in Acute Heart Failure trials. All patients were admitted for a primary diagnosis of AHF. Patients were grouped as reduced EF ≤40%, borderline 40% < EF < 50%, or preserved EF ≥50%...
April 12, 2017: American Journal of Cardiology
https://www.readbyqxmd.com/read/28476514/the-impact-of-carperitide-usage-on-the-cost-of-hospitalization-and-outcome-in-patients-with-acute-heart-failure-high-value-care-vs-low-value-care-campaign-in-japan
#9
Atsushi Mizuno, Hayato Iguchi, Yuuka Sawada, Michael Hurley, Hiroshi Nomura, Kuniyoshi Hayashi, Yasuharu Tokuda, Sachiko Watanabe, Aki Yoshikawa
BACKGROUND: The usefulness of carperitide in patients with acute heart failure (AHF) has not been confirmed; carperitide is expensive, and thus, its routine use has not been shown to add much value in clinical settings. We analyzed the impact of carperitide usage on the outcome and cost of hospitalization in AHF patients. METHODS: Data obtained from the Diagnosis Procedure Combination (DPC) database from July 2014 until June 2015 from 371 hospitals were analyzed...
April 26, 2017: International Journal of Cardiology
https://www.readbyqxmd.com/read/28463462/clinical-phenotypes-and-outcome-of-patients-hospitalized-for-acute-heart-failure-the-esc-heart-failure-long-term-registry
#10
Ovidiu Chioncel, Alexandre Mebazaa, Veli-Pekka Harjola, Andrew J Coats, Massimo Francesco Piepoli, Maria G Crespo-Leiro, Cecile Laroche, Petar M Seferovic, Stefan D Anker, Roberto Ferrari, Frank Ruschitzka, Silvia Lopez Fernandez, Daniela Miani, Gerasimos Filippatos, Aldo P Maggioni
AIMS: To identify differences in clinical epidemiology, in-hospital management and 1-year outcomes among patients hospitalized for acute heart failure (AHF) and enrolled in the European Society of Cardiology Heart Failure Long-Term (ESC-HF-LT) Registry, stratified by clinical profile at admission. METHODS AND RESULTS: The ESC-HF-LT Registry is a prospective, observational study collecting hospitalization and 1-year follow-up data from 6629 AHF patients. Among AHF patients enrolled in the registry, 13...
April 30, 2017: European Journal of Heart Failure
https://www.readbyqxmd.com/read/28459958/biased-ligand-of-the-angiotensin-ii-type-1-receptor-in-patients-with-acute-heart-failure-a-randomized-double-blind-placebo-controlled-phase-iib-dose-ranging-trial-blast-ahf
#11
Peter S Pang, Javed Butler, Sean P Collins, Gad Cotter, Beth A Davison, Justin A Ezekowitz, Gerasimos Filippatos, Phillip D Levy, Marco Metra, Piotr Ponikowski, John R Teerlink, Adriaan A Voors, David Bharucha, Kathleen Goin, David G Soergel, G Michael Felker
Aims: Currently, no acute heart failure (AHF) therapy definitively improves outcomes. Reducing morbidity and mortality from acute heart failure (AHF) remains an unmet need. TRV027 is a novel 'biased' ligand of the angiotensin II type 1 receptor (AT1R), selectively antagonizing the negative effects of angiotensin II, while preserving the potential pro-contractility effects of AT1R stimulation. BLAST-AHF was designed to determine the safety, efficacy, and optimal dose of TRV027 to advance into future studies...
April 27, 2017: European Heart Journal
https://www.readbyqxmd.com/read/28455131/echocardiographic-pulmonary-artery-pressure-estimation-and-heart-failure-rehospitalization-burden-in-patients-with-acute-heart-failure
#12
Enrique Santas, Rafael de la Espriella-Juan, Anna Mollar, Ernesto Valero, Gema Miñana, Juan Sanchis, Francisco Javier Chorro, Julio Núñez
Pulmonary hypertension (PH) is a strong predictor of mortality in patients with heart failure (HF). However, the relationship between PH, through echocardiographic pulmonary artery pressure (PASP) estimation, and the risk of HF rehospitalizations remains unclear. METHODS: We prospectively included 2343 consecutive patients discharged for acute heart failure (AHF). PH was estimated by echocardiography through PASP determination during the index admission. Patients were categorized as follows across PASP: non-measurable, normal (≤35mmHg), mild (36-45mmHg), moderate (46-60mmHg), or severe PH (>60mmHg)...
April 21, 2017: International Journal of Cardiology
https://www.readbyqxmd.com/read/28454809/day-vs-night-does-time-of-presentation-matter-in-acute-heart-failure-a-secondary-analysis-from-the-relax-ahf-trial
#13
Peter S Pang, John R Teerlink, Leandro Boer-Martins, Claudio Gimpelewicz, Beth A Davison, Yi Wang, Adriaan A Voors, Thomas Severin, Piotr Ponikowski, Tsushung A Hua, Barry H Greenberg, Gerasimos Filippatos, G Michael Felker, Gad Cotter, Marco Metra
BACKGROUND: Signs and symptoms of heart failure can occur at any time. Differences between acute heart failure (AHF) patients who present at nighttime vs daytime and their outcomes have not been well studied. Our objective was to determine if there are differences in baseline characteristics and clinical outcomes between AHF patients presenting during daytime vs nighttime hours within an international, clinical trial. METHODS: This is a post hoc analysis of the RELAX AHF trial, which randomized 1,161 AHF patients to serelaxin vs placebo, both in addition to usual AHF therapy...
May 2017: American Heart Journal
https://www.readbyqxmd.com/read/28452195/serelaxin-in-addition-to-standard-therapy-in-acute-heart-failure-rationale-and-design-of-the-relax-ahf-2-study
#14
John R Teerlink, Adriaan A Voors, Piotr Ponikowski, Peter S Pang, Barry H Greenberg, Gerasimos Filippatos, G Michael Felker, Beth A Davison, Gad Cotter, Claudio Gimpelewicz, Leandro Boer-Martins, Margaret Wernsing, Tsushung A Hua, Thomas Severin, Marco Metra
Patients admitted for acute heart failure (AHF) experience high rates of in-hospital and post-discharge morbidity and mortality despite current therapies. Serelaxin is recombinant human relaxin-2, a hormone with vasodilatory and end-organ protective effects believed to play a central role in the cardiovascular and renal adaptations of human pregnancy. In the phase 3 RELAX-AHF trial, serelaxin met its primary endpoint of improving dyspnoea through day 5 in patients admitted for AHF. Compared to placebo, serelaxin also reduced worsening heart failure (WHF) by 47% through day 5 and both all-cause and cardiovascular mortality by 37% through day 180...
April 28, 2017: European Journal of Heart Failure
https://www.readbyqxmd.com/read/28446761/metabolic-syndrome-modulates-association-between-endothelial-lipase-and-lipid-lipoprotein-plasma-levels-in-acute-heart-failure-patients
#15
Ines Potočnjak, Matias Trbušić, Sanda Dokoza Terešak, Bojana Radulović, Gudrun Pregartner, Andrea Berghold, Beate Tiran, Gunther Marsche, Vesna Degoricija, Saša Frank
We hypothesised that the established association of endothelial lipase (EL) plasma levels with atherogenic lipid profile is altered in acute heart failure (AHF) and additionally affected by overlapping metabolic syndrome (MetS). We examined the association of EL plasma levels and lipid/lipoprotein plasma levels in AHF patients without and with overlapping MetS. The study was performed as a single-centre, observational study on 152 AHF patients, out of which 85 had overlapping MetS. In the no-MetS group, EL plasma levels were significantly positively correlated with plasma levels of atherogenic lipids/lipoproteins, including total cholesterol, low-density lipoprotein (LDL)-cholesterol, total LDL particles and triglycerides, but also with plasma levels of antiatherogenic high-density lipoprotein (HDL)-cholesterol, total HDL particles and small HDL particles...
April 26, 2017: Scientific Reports
https://www.readbyqxmd.com/read/28437859/multiple-sclerosis-broke-my-heart
#16
Géraldine Androdias, Emilien Bernard, Damien Biotti, Nicolas Collongues, Françoise Durand-Dubief, Julie Pique, Ingrid Sanchez, Clément Delmas, Jacques Ninet, Romain Marignier, Sandra Vukusic
We report 5 cases of acute heart failure (AHF) related to multiple sclerosis (MS) relapses. AHF was inaugural in 3 patients, always preceded or accompanied by signs of brainstem dysfunction; it was severe, requiring intensive care management. Echocardiography showed left ventricular hypokinesis. No other cause of AHF has been found. All patients showed a new medullary lesion on brain magnetic resonance imaging. All had rapid and complete recovery of ventricular function after intravenous corticosteroids. We concluded that the cases represent a takotsubo phenomenon...
April 24, 2017: Annals of Neurology
https://www.readbyqxmd.com/read/28433323/is-there-a-clinically-meaningful-difference-in-patient-reported-dyspnea-in-acute-heart-failure-an-analysis-from-urgent-dyspnea
#17
Peter S Pang, Kathleen A Lane, Miguel Tavares, Alan B Storrow, Changyu Shen, W Frank Peacock, Richard Nowak, Alexandre Mebazaa, Said Laribi, Judd E Hollander, Mihai Gheorghiade, Sean P Collins
BACKGROUND: Dyspnea is the most common presenting symptom in patients with acute heart failure (AHF), but is difficult to quantify as a research measure. The URGENT Dyspnea study compared 3 scales: (1) 10 cm VAS, (2) 5-point Likert, and (3) a 7-point Likert (both VAS and 5-point Likert were recorded in the upright and supine positions). However, the minimal clinically important difference (MCID) to patients has not been well established. METHODS: We performed a secondary analysis from URGENT Dyspnea, an observational, multi-center study of AHF patients enrolled within 1 h of first physician assessment in the ED...
April 19, 2017: Heart & Lung: the Journal of Critical Care
https://www.readbyqxmd.com/read/28433216/implications-of-alternative-hepatorenal-prognostic-scoring-systems-in-acute-heart-failure-from-dose-ahf-and-rose-ahf
#18
Justin L Grodin, Dianne Gallup, Kevin J Anstrom, G Michael Felker, Horng H Chen, W H Wilson Tang
Because hepatic dysfunction is common in patients with heart failure (HF), the Model for End-Stage Liver Disease (MELD) may be attractive for risk stratification. Although alternative scores such as the MELD-XI or MELD-Na may be more appropriate in HF populations, the short-term clinical implications of these in patients with acute heart failure (AHF) are unknown. The MELD-XI and MELD-Na were calculated at baseline in 453 patients with AHF in the DOSE-AHF and ROSE-AHF trials. The correlations and associations for each score with cardiorenal biomarkers, short-term end points at 72 hours including worsening renal function and clinical events to 60 days were determined...
March 29, 2017: American Journal of Cardiology
https://www.readbyqxmd.com/read/28430612/diosmetin-exerts-anti-oxidative-anti-inflammatory-and-anti-apoptotic-effects-to-protect-against-endotoxin-induced-acute-hepatic-failure-in-mice
#19
You Yang, Xiao-Bao Gong, Li-Gua Huang, Zhen-Xu Wang, Rong-Zhen Wan, Peng Zhang, Qing-Yan Zhang, Zhu Chen, Bao-Shun Zhang
To investigate the effects and mechanism of diosmetin on acute hepatic failure (AHF), an AHF murine model was established through administration of lipopolysaccharides/D-galactosamine (LPS/D-GalN). In vitro, diosmetin scavenged free radicals. In vivo, diosmetin decreased mortality among mice, blocked the development of histopathological changes and hepatic damage, and suppressed levels of inflammatory mediators and cytokines. In addition, diosmetin prevented the expression of phosphorylated IKK, IκBα, and NF-κB p65 in the NF-κB signaling pathway, and JNK and p38 in the MAPK signaling pathway...
May 9, 2017: Oncotarget
https://www.readbyqxmd.com/read/28421408/pharmacological-and-non-pharmacological-treatment-for-decompensated-heart-failure-what-is-new
#20
REVIEW
Parin Shah, Pierpaolo Pellicori, Joseph Cuthbert, Andrew L Clark
PURPOSE OF THE REVIEW: Acute heart failure (AHF) is a life-threatening clinical condition that requires prompt medical attention. The aim of the current review is to summarise the results of recent clinical trials conducted in patients with AHF. RECENT FINDINGS: Several novel compounds have apparently beneficial acute effects on cardiovascular haemodynamics and patients' symptoms, but their administration has not yet translated into improved survival and has been deleterious in some cases...
April 18, 2017: Current Heart Failure Reports
keyword
keyword
39606
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"